Tarsus Pharmaceuticals, Inc. (TARS)
After hours:
| Previous close | 37.03 |
| Open | 36.68 |
| Bid | 37.96 x 100 |
| Ask | 38.09 x 100 |
| Day's range | 36.15 - 38.43 |
| 52-week range | 12.57 - 40.40 |
| Volume | |
| Avg. volume | 697,603 |
| Market cap | 1.437B |
| Beta (5Y monthly) | 1.05 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.62 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 53.38 |
ZacksDoes Tarsus Pharmaceuticals (TARS) Have the Potential to Rally 38.7% as Wall Street Analysts Expect?
The consensus price target hints at a 38.7% upside potential for Tarsus Pharmaceuticals (TARS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
GlobeNewswireTarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
IRVINE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 1.30 p.m. PT / 4.30 p.m. ET on Wednesday, May 8, 2024 to report its first quarter 2024 financial results and provide a corporate update. Participants may access the webcast here. A recorded version of the
- GlobeNewswire
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
IRVINE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it has secured $200 million in committed capital from funds associated with Pharmakon Advisors, LP. Tarsus has elected to draw $75 million on the closing date, April 19, 2024, with the remaining $125 million of committed capital avai
